All In Biotech

Drug Trial Radar · NCT02589821

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors

Last checked: Nov 20, 2026Latest source record: Mar 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

195

Planned (sponsor's estimate)

Start

Dec 7, 2015

Primary completion

Nov 11, 2019

Study completion Jul 7, 2022

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Oct 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced pancreatic neuroendocrine tumors.

Conditions

  • Neuroendocrine Tumors

Interventions

  • SurufatinibDrug

    Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle

  • PlaceboOther

    Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: 7 months after the last patient enrolled

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • the 307 Hospital of People's Liberation Army

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.